Critical discoveries over the past two decades have transformed our understanding of
medulloblastoma from a single entity into a clinically and biologically heterogeneous …

Nearly one-third of children with medulloblastoma, a malignant embryonal tumor of the
cerebellum, succumb to their disease. Conventional response monitoring by imaging and …

Simple Summary Medulloblastoma is the commonest malignant brain tumour of childhood.
Disease relapse following maximal multi-modal therapy including upfront craniospinal …

Importance Medulloblastoma recurrence in patients who have previously received
irradiation has a dismal prognosis and lacks a standard salvage regimen. Objective To …

Medulloblastoma is currently subclassified into distinct DNA methylation
subgroups/subtypes with particular clinico-molecular features. Using RNA sequencing (RNA …

Background Less than 5% of medulloblastoma (MB) patients survive following failure of
contemporary radiation-based therapies. Understanding the molecular drivers of …

Nowadays medulloblastoma (MB) tumors can be treated with risk-stratified approaches with
up to 80% success rate. However, disease relapses occur in approximately 30% of patients …

Relapse is the leading cause of death in patients with medulloblastoma, the most common
malignant pediatric brain tumor. A better understanding of the mechanisms underlying …

Deregulation of chromatin modifiers plays an essential role in the pathogenesis of
medulloblastoma, the most common paediatric malignant brain tumour. Here, we identify a …

Medulloblastoma (MB), the most common malignant pediatric brain tumor, comprises four
molecularly and clinically distinct subgroups (termed WNT, SHH, group 3, and group 4) …